Logo

Spotlight on biotech company founder, Madhu Cherukury

Spotlight on biotech company founder, Madhu Cherukury

2022-11-22

Immigrants from all over the world come to Taiwan where they find work, start families, and contribute to making the island so special. In today’s installment of “An Immigrant Story,” we meet Madhu Cherukury, an Indian man who founded a biotech company in Taiwan. The company’s specialty is developing drugs to treat diseases that affect the eye’s retina. FTV reporter Stephany Yang spoke to Cherukury about being a founder in Taiwan and some of his latest projects.

This is Madhu Cherukury, the founder of a biotech company in Taiwan. The company develops medicines that treat diseases affecting the eye’s retina, a thin layer of tissue on the inside back wall of your eye. The team currently has two projects undergoing clinical trials. One is an eye drop for dry eye disease.

Dr. Madhu Cherukury
Biotech company founder
A small molecule in-licensed from Allergan for treating dry eye disease. It’s also quite an exciting molecule. We are conducting clinical trials and testing safety and efficacy of these molecules in dry eye patients for treating for a three months period. We are expecting key clinical results this year in December.

Another project involves developing a drug to treat retinal diseases, such as diabetic macular edema and neovascular age-related macular degeneration.

Dr. Madhu Cherukury
Biotech company founder
Biologics is a protein program. A single molecule with two targets. Anti-VEGFs and anti-integrin. The anti-integrin portion of the molecule was in-licensed from NCKU in 2015. This molecule was designed to treat unmet medical needs in retinal diseases such as such as diabetic macular edema and neovascular age-related macular degeneration. This molecule is expected to improve the vision in retinal patients and prolong the effects and stop the disease progression. Currently, this project is in clinical trials. Testing the safety and efficacy of this drug. We are expecting the clinical trials in the end of the first quarter, in 2023.

Cherukury was born and raised in India. After receiving his PhD, he went to the University of Kansas Medical Center in the U.S. to complete his postdoctoral training in pharmacology and toxicology. After this, he joined the pharmaceutical industry. He then spent over 30 years developing new drugs for ophthalmology and central nervous system diseases at global companies. He first came to Taiwan in 2014, where he served as a director at a pharmaceutical company. He then founded his current biopharmaceutical company where he currently serves as the CEO. He leads a research and development team to develop medicines to treat retinal diseases such as age-related macular degeneration, dry eye, and diabetic macular edema.

Dr. Madhu Cherukury
Biotech company founder
I came to Taiwan in 2014. At that time, I was kind of concerned about Taiwan, and the language barrier. Fortunately, many Taiwanese speak English so it was not the case. Afterward, it was quite exciting to work with scientists here. I am very happy to develop the medicines, what we have today. I am quite excited about drug development. Taiwan has an excellent pool of scientists, an ecosystem and strong government support to increase new innovations. I felt I can take the advantage of Taiwan ecosystem and create a new drug development company in Taiwan and achieve the goal.

Cherukury says he hopes to continue to work with his team in Taiwan to develop new drugs to help treat more patients around the world.

人物系列: 專訪生技公司執行長馬渡 談新藥開發

2022-11-22

台灣有來自世界各地的移民,在這邊工作、建立家園並發揮所長。今天帶您來認識來一個來自印度,在台灣從事生物科技業的馬渡博士。他成了了一間生技公司,專門開發治療視網膜疾病的藥物。一起跟著英語新聞記者的腳步,一探馬渡的築夢之路。

馬渡是台灣一家生物科技公司的創辦人,公司開發治療視網膜病變的藥物,視網膜是眼睛內側後壁上的一層薄薄的組織。他們目前有兩個項目正在進行臨床試驗,其中一種是治療乾眼症的眼藥水。

[[生物科技股份有限公司執行長 馬渡]]
"一種從另一家製藥公司獲得許可的小分子,用於治療乾眼症,這是令人振奮的。我們正在進行臨床試驗,並測試這些分子在乾眼症患者中的安全性和有效性,為期三個月。我們期待今年12月的臨床結果。"

另一個項目是開發一種使用蛇毒蛋白治療視網膜疾病的藥物,例如糖尿病引起之黃斑部水腫和老年性黃斑部病變。

[[生物科技股份有限公司執行長 馬渡]]
"生物製劑是一種蛋白質程序。有兩個目標的單一分子,抗血管內皮生長因子和抗整合素。抗整合素的部分已經在2015年從成大獲得許可。主要是治療視網膜疾病,例如糖尿病黃斑水腫,和新生血管型老年性黃斑變性。這可望改善視網膜病變患者的視力,防止惡化。目前,這個項目還在臨床試驗階段,測試藥物的安全性和有效性。我們預計在2023年第一季後期臨床試驗。"

馬渡在印度出生和長大,獲得博士學位後,到美國堪薩斯醫學中心完成藥理學和毒理學博士後培訓。接著,他加入了製藥行業。在多家跨國公司工作了30多年,為眼科和中樞神經系統疾病開發新藥。他在2014年首次來到台灣,在一家製藥公司擔任董事。之後,他創立了現在的生物製藥公司,目前擔任執行長,帶領研發團隊開發治療老年性黃斑變性、乾眼症,和糖尿病黃斑水腫等視網膜疾病的藥物。

[[生物科技股份有限公司執行長 馬渡]]
"我是2014年來到台灣的,當時有點擔心在台灣會語言不通。幸運的是,許多台灣人會說英語,所以還好。在這裡和科學家合作非常開心,我很高興能夠開發我們現在的藥物。台灣擁有優秀的科學家、系統和政府大力支持,增加創新技術,我也藉著台灣的這些條件,創立開發藥物的公司,達到目標。"

馬渡表示,他希望在台灣繼續與他的團隊合作,開發新藥,造福更多患者。

Related News

DPP Taoyuan mayoral candidate Cheng Yun-peng promises to continue work on MRT

2022-11-22

Candidates across party lines canvass in campaign trucks with three days to go

2022-11-22

Railway services on East Coast to resume fully ahead of schedule on Dec. 28

2022-11-22

Black-faced spoonbills spotted hunting beside national greenway in central Tainan

2022-11-22

Analysts says TSMC expansion in Arizona will not affect Taiwan operations

2022-11-22